MedPath

Comparsion of levetiracetam and sodium valproate mono therapy in childhood epilepsy

Not Applicable
Conditions
Health Condition 1: null- newly diagnosed childhood epilepsy
Registration Number
CTRI/2017/11/010605
Lead Sponsor
ONE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Newly diagnosed focal motor or generalised epilepsy

Exclusion Criteria

1.Children who are on anti epileptic for more than 15 days

2.Children with congenital anomalies or developmental delay or microcephaly

3.Acute head trauma or post traumatic epilepsy

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Treatment will be considered successful if there is no repeat seizure activity for 6 monthsTimepoint: Treatment will be considered successful if there is no repeat seizure activity for 6 months
Secondary Outcome Measures
NameTimeMethod
1.Side effect profile of the patients in each group <br/ ><br>2.Achievement of therapeutic drug levels at steady state and 6 months <br/ ><br>3.Time to first seizure after steady state of drugTimepoint: 6 months
© Copyright 2025. All Rights Reserved by MedPath